We aim to develop an oral, small molecule to treat obesity and other metabolic disorders, with the potential for a differentiated profile relative to currently available therapies. We believe our product candidates are distinct in that they do not rely on hormonal manipulation, which is common with many obesity treatments. The program seeks to develop an oral therapeutic with certain advantages and an improved tolerability profile.

The Company has identified a lead compound for continued preclinical evaluation. The Company completed two non-GLP (Good Laboratory Practice) pharmacology studies, establishing proof-of-concept in the diet induced obesity (DIO) mouse model. Observations from the studies conducted were encouraging and consistent with statistically significant dose-related reductions in body weight. Notably, the data indicated statistically significant improvements in body composition, specifically percentage fat and relative preservation of percentage lean, alongside favorable changes in metabolic parameters. We continue to conduct preclinical activities intended to inform the planning of investigational new drug (IND)-enabling studies.